Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
Lantheus's lutetium-177 dotatate ANDA (PNT2003), the first radioequivalent to Novartis's Lutathera, received FDA tentative approval on March 2, 2026; full approval is gated by the expiration of the 30-month Hatch-Waxman stay in June 2026. PNT2003 would launch into the gastroenteropancreatic neuroendocrine-tumor (GEP-NET) market alongside Lutathera and ahead of ITM-11 (Lu-edotreotide-177), which carries an August 28 PDUFA. Lantheus licensed PNT2003 from POINT Biopharma in December 2022, before Lilly's POINT acquisition.
AMC Defense Law's June 2026 'Justice Watch' note read the peptide enforcement signal: compounding pharmacies receiving warning letters and losing licenses, telehealth companies facing criminal indictments, and bulk-substance vendors under federal scrutiny. The FDA has issued more than 50 warning letters to peptide vendors and compounders in 2024-2025, and the agency has signaled an aggressive 503A/503B stance heading into the July 23-24 PCAC meeting that will rule on whether seven peptides return to legal compounding status.
The FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list approaches its June 29 comment-window close. Once finalized, the rule effectively bars large-scale compounding of these GLP-1s under any clinical-need exception, accelerating the wind-down already underway among compounders (ProRx, BPI Labs, the Hims-affiliated manufacturer Medisource). Compounded GLP-1 telehealth platforms have largely pivoted to branded-drug fulfillment or microdose protocols, with the regulatory cliff at three weeks out.
A June 9 Pharmacy Times analysis broke down what HHS Secretary Robert F. Kennedy Jr.'s February 27 announcement of Category 2 to Category 1 reclassification actually means for licensed compounding pharmacies. The piece emphasized that reclassification does not mean FDA approval and that BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, and MOTS-C still need PCAC review on July 23-24 before formal addition to the 503A bulks list. Google search volume for 'peptides' rose from 1.3 million per month in 2024 to roughly 8 million per month in 2026.
The ADA closed its 86th Scientific Sessions on June 8 with a formal revision to its Standards of Care that elevates cardiovascular and kidney risk reduction to a co-primary treatment goal alongside glycemic control, ending decades of practice in which HbA1c stood as the dominant benchmark. The shift formalizes a redefinition of diabetes care around the cardio-renal-metabolic axis that GLP-1, SGLT2, and finerenone evidence has driven, and pushes earlier GLP-1 and SGLT2 use from diabetes diagnosis.
On Saturday June 6, the Obesity Association (a division of the ADA) released the first stand-alone ADA Standards of Care in Overweight and Obesity: 34 new recommendations across seven sections, with a new pharmacologic-treatment section and a target of sustained body-weight reduction of at least 5%. The standards push obesity drugs from off-label discretion into anchored clinical-appropriateness criteria, the framework health systems and payers will use to write coverage policy.
Camurus' Oclaiz (CAM2029), a once-monthly subcutaneous octreotide depot built on the company's FluidCrystal technology and delivered by autoinjector pen, carries an FDA PDUFA target date of June 10 for acromegaly. The resubmitted NDA, accepted after a Complete Response Letter tied to a third-party manufacturing inspection, rests on seven clinical studies including the two Phase 3 ACROINNOVA trials. A clearance would add a peptide depot to the somatostatin-analog market alongside Crinetics' newly launched oral Palsonify.
With EASL and ASCO dominating the clinical-data cycle, the FDA peptide-compounding regulatory track continues moving toward the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting. Twelve peptides came off the FDA Category 2 'significant safety risk' bulks list effective April 23, 2026; seven of those (BPC-157, TB-500, KPV, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) advance to the July PCAC for affirmative 503A bulks-list inclusion. A second PCAC before end of February 2027 reviews five more (GHK-Cu injectable, Melanotan II, Cathelicidin LL-37, Dihexa, PEG-MGF). Removal from Category 2 does not yet permit compounding — that requires the affirmative PCAC recommendation plus FDA final determination (6-12 month timeline). The parallel 503B bulks-list proposal excluding semaglutide, tirzepatide, and liraglutide closes public comments June 29. The compounded-semaglutide shipment volume is down 90% year-over-year per the BSR Intelligence briefing as the regulatory vise tightens on the gray-market segment.
The FDA granted accelerated approval on May 22, 2026 to Gilead Sciences' Hepcludex (bulevirtide-gmod) 8.5 mg, the first and only approved US treatment for adults living with chronic hepatitis delta virus (HDV) infection. Bulevirtide — formerly known as Myrcludex B — is a 47-amino acid, N-terminally myristoylated lipopeptide derived from the pre-S1 domain of the HBV large envelope protein. The molecule binds to the sodium taurocholate cotransporting polypeptide (NTCP) — the entry receptor that HDV and HBV both use to enter hepatocytes — and blocks viral entry as a first-in-class entry inhibitor. The Phase 3 MYR301 trial documented a statistically significant combined virologic and biochemical response at week 48 versus delayed-treatment control, supporting the accelerated-approval threshold. Continued approval depends on confirmatory trial verification of clinical benefit. Bulevirtide has been EU-approved under conditional marketing authorization since 2020. Gilead shares closed Friday at $134.36, up roughly 3%.
Novo Nordisk announced May 22 that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency adopted a positive opinion recommending marketing authorization of Wegovy 7.2 mg in a single-dose pen for adults living with obesity. Wegovy 7.2 mg is the high-dose once-weekly injectable formulation already available in the US as Wegovy HD. The STEP UP Phase 3 trial demonstrated 20.7% mean weight loss with the 7.2 mg dose, with approximately one in three participants experiencing ≥25% weight loss; in the STEP UP T2D trial, the same dose produced 14.1% mean weight loss in adults with obesity and type 2 diabetes. Novo expects to launch Wegovy 7.2 mg in the EU in Q3 2026. The CHMP opinion arrived the same day as the parallel positive recommendation for Wegovy pill (oral semaglutide 25 mg) — completing Novo's twin EU regulatory wins for the higher-dose injectable and the oral formulation simultaneously.
Novo Nordisk announced on May 22 that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency adopted a positive opinion recommending marketing authorization of Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain long-term weight reduction. The recommendation includes data from SELECT in the label — the cardiovascular outcomes trial that documented a 20% major adverse cardiovascular event reduction with injectable Wegovy. The CHMP opinion is the first oral GLP-1 EU approval recommendation for weight management. OASIS 4 Phase 3 data anchoring the filing: 16.6% mean weight loss in adults with obesity or overweight plus one comorbidity, comparable to injectable Wegovy 2.4 mg. Novo plans to launch the pill in select non-US markets in H2 2026, with UK, Germany, and Denmark previously flagged as the first international launches (CNBC May 18). The CHMP opinion confirms the international expansion path Novo's EVP Larsen described.
The FDA sent a warning letter to Harbin Jixianglong Biotech disclosed May 20 after inspectors discovered a compliance failure at the company's manufacturing facility two months after the firm had been added to the FDA's green list to export GLP-1 drugs to the US. Jixianglong allegedly bought semaglutide active pharmaceutical ingredient from a facility not on the green list, labeled the API as manufactured at its own plant (implying the green-listed origin), and shipped the batch to US customers. The FDA framed the labeling as an apparent attempt to circumvent import-alert safeguards. The agency's March 11 enforcement report had previously listed Jixianglong recalls of semaglutide for compounding use only, attributed to failing to complete process validation and bacterial endotoxin method validation before distribution. The action is part of the broader FDA Pharmaceutical Quality / GLP-1 supply-chain enforcement cycle, including the April 30 503B bulks-list proposal closing June 29.
Pharmacy Times hosted a CME-eligible virtual symposium May 19 (1:00-2:30 PM EDT) framing the post-RFK Jr. peptide moment for hospital and retail pharmacists. The agenda crossed the wellness-clinic side (BPC-157, TB-500, CJC-1295, GHK-Cu after the April 22 503A Category-2 removal) with the FDA-approved peptide side (semaglutide, tirzepatide, liraglutide, navepegritide, paltusotine) and walked attendees through the July 23-24 PCAC vote calculus and patient counseling around compounded GLP-1 risk.
The FDA confirmed the Pharmacy Compounding Advisory Committee will convene a second meeting before the end of February 2027 to review five additional peptides for potential 503A Bulk Drug Substances List inclusion: GHK-Cu (injectable formulation specifically — topical/cosmetic remains separate), Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and Mechano Growth Factor Pegylated (PEG-MGF). The February 2027 meeting follows the July 23-24, 2026 PCAC that will review seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2). Compounding pharmacies cannot legally compound these five peptides until the PCAC review concludes and the FDA issues a final determination — a 6-12 month timeline post-meeting. The peptide-specific indications under review span aesthetic dermatology (GHK-Cu, Melanotan II), antimicrobial activity (LL-37), neuroprotection (Dihexa), and growth-factor-mediated tissue regeneration (PEG-MGF).
The Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 — at which seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) will be discussed for 503A compounding inclusion — now has firm public-comment deadlines. Written submissions are due July 9, 2026 via regulations.gov; oral presentation requests close June 30, with the FDA allocating presentation slots after review. The PCAC review follows the April 23, 2026 effective date when 12 peptides came off the FDA's Category 2 bulks list. Industry stakeholders, patient groups, and clinicians are organizing through the SSRPi network and the Alliance for Pharmacy Compounding to coordinate testimony. The combined regulatory cycle — PCAC plus the parallel April 30 503B bulks-list proposal closing June 29 — will reshape the compounding-pharmacy economy through 2027 and determine which research peptides remain accessible through licensed channels.
The FDA announced an AI-Informed Inspection Pilot on May 15, 2026, applying machine-learning analysis to facility inspection prioritization and execution. The program is part of the FDA's Pharmaceutical Quality/Manufacturing Standards initiative and will affect peptide-manufacturing sites including 503A compounding pharmacies, 503B outsourcing facilities, and full-scale peptide CDMOs. AI inputs include historical inspection findings, FAERS adverse-event signals, supply-chain risk indicators, and recall history. The pilot lands during a sensitive compounding-pharmacy regulatory cycle ahead of the July 23-24 PCAC meeting on seven peptides for 503A bulks-list inclusion (BPC-157, KPV, TB-500, MOTs-C, Emideltide/DSIP, Semax, Epitalon) and against the April 30 503B bulks-list proposal closing comments June 29. Industry response is mixed: faster inspection cycles could ease compliance burden for well-run facilities but may concentrate enforcement on the gray-market segment.
The FDA updated its Section 503A bulks drug substances list on May 14, 2026, continuing the rolling-status changes leading into the July 23-24 PCAC meeting that will evaluate seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) for potential 503A-bulks-list inclusion. The April 30 503B bulks-list proposal (closing June 29) is moving in parallel toward effectively ending large-scale 503B compounding of semaglutide, tirzepatide, and liraglutide. The combined regulatory cycle through July 24 will reshape the compounding-pharmacy economy for the next 2-3 years and determine which research peptides remain accessible through licensed channels.
Oncopeptides AB announced May 11-12 it intends to submit a Type II variation application to the European Medicines Agency to expand the Pepaxti (melflufen) label to include third-line treatment of relapsed/refractory multiple myeloma. Pepaxti is one of two FDA-approved peptide-drug conjugates currently on market (the other being Novartis's 177Lu-dotatate Lutathera) and acts as a melphalan-flufenamide alkylating peptide that exploits aminopeptidase enzymes overexpressed in myeloma plasma cells to selectively release the cytotoxic payload inside tumor cells. The Pepaxti EMA label currently covers heavily pre-treated (≥4 prior lines) RRMM; the new third-line expansion submission would meaningfully extend the eligible population. The filing positions the PDC modality for a broader regulatory footprint as the broader peptide-drug-conjugate field heads into ASCO 2026.